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Summary
OBJECTIVE Serum IGF-I levels are monitored during
GH replacement treatment in adults with GH de®-
ciency (GHD) to guide GH dose adjustment and to
minimize occurrence of GH-related side-effects. This
is not routine practice in children treated with GH. The
aim of this study was to evaluate changes in (1) serum
IGF-I, IGFBP-3 and IGF-I/IGFBP-3 molar ratio, and (2)
serum leptin, an indirect marker of GH response,
during the ®rst year of GH treatment in children with
disordered growth.
DESIGN An observational prospective longitudinal
study with serial measurements at ®ve time points
during the ®rst year of GH treatment was carried out.
Each patient served as his/her own control.
PATIENTS The study included 31 patients, grouped
as (1) GHD (n20) and (2) non-GHD (Turner syndrome
n 7; Noonan syndrome n4), who had not pre-
viously received GH treatment.
MEASUREMENTS Serum IGF-I, IGFBP-3 and leptin
levels were measured before treatment and after
6 weeks, 3 months, 6 months and 12 months of GH
treatment, with a mean dose of 0´5 IU/kg/wk in GHD
and 0´7 IU/kg/wk in non-GHD groups. IGF-I, IGFBP-3
and the calculated IGF-I/IGFBP-3 molar ratio were
expressed as SD scores using reference values from
the local population.
RESULTS In the GHD group, IGF-I SDS before treat-
ment was lower compared with the non-GHD (ÿ5´4 6
2´5 vs. ÿ1´8 6 1´0; P < 0´001). IGF-I (ÿ1´8 SDS 6 2´2)
and IGFBP-3 (ÿ1´1 SDS 6 0´6) levels and their molar
ratios were highest at 6 weeks and remained relatively
constant thereafter. In the non-GHD group, IGF-I
levels increased throughout the year and were maxi-
mum at 12 months (0´3 SDS 6 1´4) while IGFBP-3
(1´1 SDS 6 0´9) and IGF-I/IGFBP-3 molar ratio peaked
at 6 months. In both groups, IGF-I SDS and IGF-I/
IGFBP-3 during treatment correlated with the dose of
GH expressed as IU/m2/week (r-values 0´77 to 0´89;
P 0´005) but not as IU/kg/week. Serum leptin levels
decreased signi®cantly during GH treatment in the
GHD (median before treatment 4´0 mg/l; median after
12 months treatment 2´4 mg/l; P 0´02) but not the non-
GHD (median before treatment 3´0 mg/l; median after
12 months treatment 2´6 mg/l). In the GHD group,
serum leptin before treatment correlated with 12
month change in height SDS (r 0´70, P 0´02).
CONCLUSIONS The pattern of IGF-I, IGFBP-3 and
their molar ratio during the ®rst year of GH treatment
differed between the GHD and non-GHD groups. Cal-
culation of GH dose by surface area may be preferable
to calculating by body weight. As a GH dose-depen-
dent increase in serum IGF-I and IGF-I/IGFBP-3 may
be associated with adverse effects, serum IGF-I and
IGFBP-3 should be monitored routinely during long-
term GH treatment. Serum leptin was the only variable
that correlated with ®rst year growth response in
GHD.
GH has been used for over 25 years as replacement for GH
de®ciency (GHD) in children and for over 10 years to
promote growth in conditions such as Turner syndrome. The
best dose and regimen, the most accurate short-term
parameter of treatment success and reliable indicators of
potential side-effects have yet to be de®nitively determined.
GH induces hepatic and local tissue production of IGF-I and
raises IGF-I and IGFBP-3 levels (the principal carrier protein
of IGF-I) in serum. In GHD adults, GH dose-dependent
changes in serum IGF-I, serum IGFBP-3 and adverse effects
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have been observed (de Boer et al., 1996; Johannsson et al.,
1997), and serum IGF-I levels are monitored during treatment
to guide GH dose adjustment and to minimize occurrence of
adverse effects. The recommended target serum IGF-I range
during treatment in adults varies among investigators (61 SD
or 62 SD of age-related normal range) (de Boer et al., 1996;
BuÈlow et al., 1999; Murray et al., 1999) and the optimal
range has not been de®ned. Serum IGF-I and IGFBP-3
concentrations are not routinely monitored during GH
treatment in children, and the dose of GH tends to be
adjusted according to the growth response.
The aim of this study was to evaluate changes in serum
IGF-I, IGFBP-3 and IGF-I/IGFBP-3 molar ratio over the
®rst year of GH treatment in children to assess GH
sensitivity and the possible role of these peptides as markers
of compliance or overtreatment. Serum leptin is another
potential marker, albeit indirect, of GH response. A fall in
plasma leptin and fat stores associated with GH treatment
has been reported in GHD adults (Florkowski et al., 1996;
Janssen et al., 1997) and children (Rauch et al., 1998;
KristroÈm et al., 1998; Matsuoka et al., 1999). We therefore
examined the changes in serum leptin concentrations during
GH replacement and in relation to changes in growth and
body mass index.
Subjects and methods
The study included 31 children (age 1´7±15´9 years; 14 girls)
with disordered growth, not previously treated with GH,
recruited from three centres. They were categorized into two
groups: (1) 20 children (seven girls) with GHD (15 with
isolated GHD and ®ve with multiple pituitary hormone
de®ciency), and (2) 11 children with non-GHD (seven with
Turner syndrome and four with Noonan syndrome). In addition
to typical phenotypic features and appropriate auxological
characteristics, the diagnosis of GHD was based on peak
stimulated GH level less than 15 mU/l (n 18) or peak
stimulated GH level 15±17 mU/l and pituitary stalk transection
on MRI (n 2). GHD was idiopathic (n 13) or associated
with craniopharyngioma (n 3), radiotherapy (n 3) or septo-
optic dysplasia (n 1). The diagnoses of Turner syndrome and
Noonan syndrome were con®rmed by karyotype and experi-
enced clinicians, respectively. None of the female patients
received oestrogen during this period. The clinical character-
istics of the two groups are shown in Table 1. Ethical committee
approval and consent were obtained prior to the study from all
children (if old enough) and their parents.
Recombinant human GH was administered subcutaneously
before bedtime, 6 or 7 days a week, at a dose of 0´5 (SD 0´1)
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Table 1 Clinical and biochemical characteristics of the 20 children with GH de®ciency (GHD) and 11 children with non-GHD (Turner syndrome and
Noonan syndrome). Data are presented as median, mean, SD and range
GHD Non-GHD
Median Mean SD Range Median Mean SD Range
Before GH treatment
Age (years) 9´3 9´1 3´7 3´4 to 15´2 9´8 9´4 4´0 1´7 to 15´9
Bone age (years) 4´6 6´3 3´5 1´5 to 13´0 10´2 9´3 3´8 3´0 to 13´0
Serum IGF-I (mg/l) 32 88 99 11 to 386 150 198 115 100 to 381
IGF-I SDS ± 5´4 ± 5´4 2´5 ± 10´7 to ÿ 1´4a ± 1´9 ± 1´8 1´0 ± 3´0 to ÿ 0´1a
Serum IGFBP-3 (mg/l) 1´3 1´3 0´5 0´5 to 1´9 1´6 1´5 0´3 0´9 to 2´0
IGFBP-3 SDS ± 2´2 ± 2´0 0´7 ± 2´9 to 0 ± 1´8 ± 1´9 0´7 ± 3´0 to ÿ 1´0
Serum IGF-I/IGFBP-3 ratio 0´2 0´4 0´4 0´03 to 1´9 0´6 0´7 0´4 0´3 to 1´4
IGF-I/IGFBP-3 ratio SDS ± 1´4 ± 1´4 0´9 ± 2´9 to 1´6 ± 0´9 ± 0´3 1´1 ± 1´3 to 1´8
Serum leptin (mg/l) 4´0 9´1 11´7 3´0 to 37´4 3´0 3´2 0´9 2´3 to 4´4
Height velocity (cm/year)
Before 3´9 4´0 1´2 2´5 to 7´2b 4´7 4´4 1´0 2´9 to 5´6c
First 12 months 9´6 9´9 2´6 7´0 to 15´4b 7´5 7´5 1´6 4´6 to 10´8c
Height SDS
At start ± 2´9 ± 2´8 1´4 ± 6´0 to 0´1d ± 2´5 ± 2´7 0´9 ± 4´1 to ÿ 1´6e
At 12 months ± 2´0 ± 1´9 1´4 ± 5´1 to 1´0d ± 2´1 ± 2´2 0´7 ± 3´4 to ÿ 1´3e
BMI SDS
At start 0´3 0´6 1´5 ± 1´9 to 4´1f 0 0´1 1´4 ± 2´9 to 2´2
At 12 months ± 0´3 0´1 1´5 ± 3´7 to 3´1f 0´1 0 1´1 ± 1´5 to 1´8
a±dP < 0´001; eP 0´01; fP 0´03.
IU/kg/week in GHD and 0´7 (SD 0´1) IU/kg/week in non-GHD
patients. The mean dose of GH expressed according to body
surface area was 15´3 IU/m2/wk (SD 3´3, range 10´0±21´2) for
the GHD and 19´8 IU/m2/wk (SD 4´8, range 13´3±29´2) for the
non-GHD group.
Height, weight, serum IGF-I, IGFBP-3 and leptin levels were
measured before and at four time points (6 weeks, 3 months,
6 months, 12 months) after commencing GH treatment. Height,
weight and BMI (weight/height2) were converted to SD scores
using 1990 UK standards (Cole et al., 1995; Freeman et al.,
1995). Blood samples for serum IGF-I, IGFBP-3 and leptin
were taken approximately 14±16 h after the last dose of GH.
Biochemical assays
Serum IGF-I was measured by a previously reported in-house
radioimmunoassay (RIA) method (Gill et al., 1997). The
sensitivity of the assay was 0´8 mg/l and the intra- and interassay
CVs were 4´0±5´7% and 5´2±7´4%, respectively. Serum
IGFBP-3 was measured using a commercial double antibody
RIA (Bioclone Australia Ltd, Sydney, Australia). The sensi-
tivity of the assay was 3´5 mg/l and the intra-and interassay CVs
were 4´3% and 6´6%, respectively. For calculation of the molar
ratio between IGF-I and IGFBP-3, the following molecular
massess were used: IGF-I 7´5 kD and IGFBP-3 42´0 kD. Values
for IGF-I, IGFBP-3 and IGF-I/IGFBP-3 molar ratio were
expressed as age, sex and puberty speci®c SD scores using
reference values obtained from our local population of healthy
children (Hall et al., 1998; Hall et al., 1999). Serum leptin was
measured using a commercial RIA (Linco, St Charles, MO,
USA). The limit of detection of the assay was 0´5 mg/l. The intra-
and interassay CVs ranged from 3´4 to 8´3% and 3´6±6´2%,
respectively, over a leptin concentration range of 4´9±25´6 mg/l.
Statistical analysis
Values at different time points were compared by one-way
repeated analysis of variance, followed by paired t-tests with a
Bonferroni correction where signi®cant (P < 0´05) differences
were found. Leptin concentrations were log-transformed prior
to analyses. Relationships between variables were evaluated by
Pearson correlations and linear regression analysis.
Results
Growth response to GH treatment
Height velocity during the ®rst year of GH treatment was
signi®cantly greater than that prior to treatment in both groups
(Table 1). Change in height SDS in response to GH treatment
showed wide variation in both groups. Mean change in height
SDS during the ®rst year of GH treatment was signi®cantly
higher (P 0´05) in the GHD group (0´8; SD, 0´5) than the non-
GHD group (0´5; SD, 0´3). Mean change in BMI SDS during
this period was also signi®cantly greater (P 0´05) in the GHD
group (ÿ 0´5; SD, 0´7) compared to the non-GHD group
(ÿ 0´06; SD, 0´7).
Pretreatment serum IGF-I, IGFBP-3 and IGF-I/IGFBP-3
molar ratio
Pretreatment serum IGF-I SDS but not IGFBP-3 SDS was
lower in the GHD compared with the non-GHD group
(P < 0´001) (Table 1). Serum IGF-I levels were below ÿ 2
SDS in all but one patient with GHD (ÿ1´4 SDS). IGF-I/
IGFBP-3 molar ratios were below ÿ 2 SDS in ®ve patients with
GHD but within 2 SDS in all non-GHD patients.
Changes in serum IGF-I, IGFBP-3 and IGF-I/IGFBP-3
molar ratio during GH treatment
GHD group. Serum IGF-I and IGFBP-3 levels increased
signi®cantly during treatment in the GHD group (Fig. 1a, b).
The major increment in IGF-I in the GHD group was achieved
by 6 weeks (Fig. 1a, b). IGF-I SDS increased at least 1´0 SDS
in all but one patient (a 4-year-old boy: IGF-I SDS before and
on GH±5´7 and ÿ 5´6, respectively). However, mean IGF-I
SDS remained in the low normal range and levels did not
increase above ÿ 2´0 SDS of the reference values in 7 of the
20 patients. The pattern of changes in IGFBP-3 levels (Fig. 1b)
and IGF-I/IGFBP-3 molar ratios (Fig. 1c) was similar to that
in IGF-I.
Non-GHD group. In the non-GHD group, IGF-I levels
increased progressively throughout the year and reached a
maximum at 12 months (Fig. 1d) while IGFBP-3 (Fig. 1e) and
IGF-I/IGFBP-3 molar ratio (Fig. 1f) peaked at 6 months.
Relationship between serum IGF-I and IGFBP-3 and the
growth response to GH treatment
Neither serum IGF-I, IGFBP-3, IGF-I/IGFBP-3 molar ratio nor
the changes in values during treatment were predictive of
annual height gain in either group. However all four GHD
patients with change in IGF-I at 6 weeks < 2´5 SDS had a poor
increment in height over 12 months' treatment of < 0´75 SDS
(Fig. 2). Of the GHD patients with change in IGF-I at 6 weeks
$ 2´5 SDS, 31% had a poor increase in height over 12 months
of < 0´75 SDS while 69% had an increment $ 0´75 SDS.
Relationship between serum IGF-I, IGFBP-3 and
IGF-I/IGFBP-3 molar ratio and the dose of GH
During GH treatment, IGF-I SDS and IGF-I/IGFBP-3 molar
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Fig. 1 Serum IGF-I (a and d), IGFBP-3 (b and e) and IGF-I/IGFBP-3 molar ratio (c and e) before and during treatment with GH in (a-c) GHD and (d-f) non-GHD groups. Values are
expressed as SDS. Mean and standard deviation are shown by the mean and error bar plots.
ratio correlated positively with GH dose/m2/week, but not dose/
kg/week, in both study groups. The relationship was strongest
at 3 months (GHD: IGF-I SDS r 0´77, P < 0´001; IGF-I/
IGFBP-3 r 0´89, P < 0´001. Non-GHD: IGF-I SDS r 0´78,
P 0´005; IGF-I/IGFBP-3 r 0´87, P < 0´001). The relation-
ship between GH dose and IGFBP-3 SDS was not signi®cant in
either group.
Exceptionally high and low biochemical values in
individual patients
In the GHD group, the highest IGF-I/IGFBP-3 molar ratio (6´3
SDS) was seen in an 11-year-old girl with isolated GHD and
coexisting asthma after her dose of inhaled beclomethasone
dipropionate was halved from 1600 mg/day to 800 mg/day at
3 months (change in height SDS with GH replacement was 0´6
SDS; dose of GH 18´5 IU/m2/week). One 12-year-old patient
with craniopharyngioma had high IGF-I (2´9 SDS) and IGF-I/
IGFBP-3 molar ratio (3´4 SDS) during treatment (dose 18´4 IU/
m2/week), when his height SDS increased by 1´3 SDS.
IGF-I levels (2´3, 2´1, 2´1 SDS) and corresponding IGF-I/
IGFBP-3 molar ratios (5´3, 7´2, 5´4 SDS) were greater than
 2´0 SDS in 3 girls with Turner syndrome during GH
treatment (dose 29´2, 24´3 and 21´6 IU/m2/week). Their
change in height SDS with treatment was 0´1, 0´3 and 0´6
SDS, respectively.
IGF-I and IGFBP-3 SD scores after commencing GH
treatment were lower than pretreatment values in two girls
with Turner syndrome (GH dose 13´3 and 18´8 IU/m2/week;
increase in height 1´3 and 0´3 SDS, respectively).
Serum leptin before and during GH treatment
Suf®cient sample volumes to measure serum leptin were
available from 11 and four unselected children with GHD and
non-GHD, respectively. Serum leptin levels decreased sig-
ni®cantly during GH treatment in the GHD (being lowest at
12 months: median 2´4, interquartile range 2´3±3´0 mg/l;
P 0´02) but not the non-GHD group (median at 12 months
2´6, interquartile range 2´1±3´5 mg/l). In the GHD group, serum
leptin concentration before treatment correlated with BMI SDS
at the start (r 0´77, P 0´01), serum IGF-I SDS after 6 week
(r 0´77, P 0´006), IGF-I/IGFBP-3 after 6 week (r 0´74,
P 0´009) and change in height SDS (r 0´70, P 0´02) but
not change in BMI during 12 months' treatment.
Discussion
The pattern of serum IGF-I and IGFBP-3 levels, and IGF-I/
IGFBP-3 molar ratio during the ®rst year of treatment differed
between the GHD and non-GHD groups. It may be explained by
the differences in GH secretory status, GH responsiveness,
pretreatment IGF-I and IGFBP-3 levels and modulation by
GHBP (GH receptor). The positive relationship between the
dose of GH and serum IGF-I but not serum IGFBP-3 suggests
that IGF-I is more sensitive to GH than IGFBP-3. The increase
in IGF-I/IGFBP-3 molar ratio with increasing dose of GH may
re¯ect an increase in bioavailable IGF-I.
Our observation of a reduction in serum leptin levels during
GH replacement in GHD children complements previous
studies (KristroÈm et al., 1998; Rauch et al., 1998; Matsuoka
et al., 1999). It raises the possibility of biological endpoints
other than growth, such as body composition, and is likely to be
a re¯ection of decreased fat mass: a relationship between the
reduction in serum leptin and change in total body fat
(estimated by dual-energy X-ray absorptiometry) during GH
treatment has been reported (Matsuoka et al., 1999). Our
observations and those of KristroÈm et al. (1998) suggest that
basal leptin concentration is correlated to the growth promoting
effect of GH. A number of observations indicate a potential link
between leptin/body fat, GH receptor expression and response
to GH (Martha et al., 1992; Bjarnason et al., 1997; Florkowski
et al., 1999).
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Fig. 2 Relationship between change in serum IGF-I at 6 weeks and
increment in height SDS during 12 months' GH treatment in patients
with GHD. The dotted lines represent the cut-offs for change in
serum IGF-I at 6 weeks (2´5 SDS) and 12 month increment in height
(0´75 SDS).
Leptin levels during GH treatment have not previously been
reported in Turner syndrome or Noonan syndrome. The lack of
complete data on all patients at all time points may have
precluded us from identifying a signi®cant fall in leptin levels
during treatment. On the other hand, as there was little change
in BMI during GH treatment, it is likely that leptin levels do not
change signi®cantly in these syndromes.
In GHD adults, considerable variability in responsiveness to
GH, and relationships with GH dose, pretreatment GHBP
levels, age and gender have been observed for different GH
effects (including increase in serum IGF-I (Bengtsson et al.,
1993; BuÈlow et al., 1999), serum IGFBP-3 (de Boer et al.,
1996; Chipman et al., 1997), changes in body composition
(Johannsson et al., 1996) and glucose tolerance (Beshyah et al.,
1995). The growth response to GH (Sherman et al., 1987;
Schwartz et al., 1990; Martha et al., 1992; Blethen et al., 1993;
KristroÈm et al., 1995; KristroÈm et al., 1997; KristroÈm et al.,
1998; Ranke et al., 1999) has been the main issue in children
and adverse effects (Blethen & MacGillivray, 1997) of
treatment have received less attention. In our study, serum
leptin concentration before treatment was the only variable that
correlated with the ®rst year growth response to GH in children
with GHD. The relatively small number of subjects may have
precluded us from identifying other important explanatory
variables. Unlike Schalch et al. (1982); Mandel et al. (1995)
and KristroÈm et al. (1997), but in keeping with other
investigators (Rosenfeld et al., 1981;Dean et al., 1982), we
did not ®nd changes in IGF-I nor IGFBP-3 to be major
correlates of growth rate during GH replacement in patients
with GHD. But we did show that a satisfactory growth response
did not occur if the IGF-I response to treatment was low.
The increase in serum IGF-I and IGFBP-3 concentrations,
and IGF-I/IGFBP-3 molar ratios observed during GH treatment
has a number of implications. First, titrating the dose of GH to
maintain serum IGF-I and IGFBP-3 within age dependent
normal ranges is physiologically sound and analogous to
monitoring replacement treatment for other endocrine de®-
ciencies such as hypothyroidism. High values in some children
but minimal response in others illustrates the need for
individualized GH dosage. Second, as we observed in one
patient with GHD and two girls with Turner syndrome,
monitoring IGF-I levels during GH treatment offers the
possibility of identifying noncompliance. Third, GH dose-
dependent changes in IGF-I and IGFBP-3 may be associated
with adverse effects in children and safety needs to be
considered for GH replacement in GHD as well as for
pharmacological treatment in non-GHD as treatment is likely
to be continued for many years (Baens-Bailon et al., 1992;
MacGillivray et al., 1998). Although we found that girls with
Turner syndrome were more likely to have abnormally high
IGF-I levels during GH treatment, one patient with GHD also
had high IGF-I concentrations despite a conventional replace-
ment dose of GH. Potential fears related to longterm cancer risk
have been well publicised (Chan et al., 1998; Hankinson et al.,
1998; Orme et al., 1998; Yu et al., 1999). As the oncogenic
potential is likely to be greatest in patients with high IGF-I and
low IGFBP-3 concentrations (Hankinson et al., 1998; Petridou
et al., 1999; Yu et al., 1999) it seems prudent to monitor IGF-I
and IGFBP-3 levels during GH treatment in children.
The change in serum IGF-I and IGFBP-3 in response to GH,
as an index of the extent of GH responsiveness and the potential
for adverse effects, may facilitate decision making, especially
when treatment with higher doses is contemplated in children
demonstrating poor growth with conventional doses. Monitor-
ing is likely to be easy in practical terms with the availability of
IGF-I and IGFBP-3 measurements from ®nger prick blood
spots but raises a number of questions which will need to be
addressed by further studies: how frequently serum IGF-I and
IGFBP-3 levels should be monitored, and when and how the
dose of GH should be modi®ed with reference to these levels
and an individual child's growth response.
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